Hui Xin Ong. (YY)

Dr. Hui Xin Ong (YY) is the chief scientific officer (CSO) of Ab-Initio Pharma, a contract development and manufacturing (CDMO) company in Sydney that helps innovators take their novel therapies to clinic. She also holds academic positions at Macquarie Medical School and a Research Leader at the Woolcock Institute of Medical Research, ranked no.1 globally for respiratory and sleep research. With a PhD in Pharmaceutical Science from University of Sydney, her research is focused on developing pharmaceutical and device technologies that can be used for the treatment of upper and lower respiratory diseases, and methodological platforms that can help promote the translation of new discoveries to the clinic. Specifically, Dr Ong's expertise lies in studying the dynamic interactions between the different biological barriers in the respiratory tract and aerosol particles in a representative manner that captures the true nature of aerosol interactions in the airways. She has worked with diverse experts from academia and industry partners leading to development of various state-of-the-art pharmaceutical formulations, IPs and outstanding publication record in leading journals in the field. Dr Ong’s well-rounded experience in industry focused research, applied and clinical research aims to translate her research into commercial outcomes that will benefit the healthcare sector and community. She has been awarded the 2021 Drug Delivery to the Lung Emerging Scientist Award and the International Society of Aerosol Medicine Young Investigator Award 2023 in recognition of her international reputation as an early career researcher contributing to inhalation medicines.